In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Russian IP Status: Adequate, But Flawed For Pharma

Executive Summary

In recent years, Russia has adopted IP reforms that bring its patent provisions closer to international standards, but enforcement remains problematic, as are dispute proceedings, in part because there’s a lack of trained judicial experts.

You may also be interested in...



Priming Russia’s Pharma Industry For Innovation

The Russian government’s aggressive plan to modernize the country’s pharmaceutical industry is stimulating entrepreneurial activities, as well as a flurry of deal activity between local and foreign companies. Many uncertainties remain about the potential opportunities, however, as foreign companies try to sort out changing regulatory and business dynamics.

EU Business News: Biofarma Gets New PE Owners; Montefarmaco Strikes Ipsen Deal; Stada Expands Production Network

Round-up of the latest European consumer health market news: Private-equity firm Ardian acquires Italian supplements and cosmetics manufacturer Biofarma; Montefarmaco OTC strikes deal with Ipsen for GI lines; and Stada expands its production network with new Romania site.

FDA Publishes Raft Of Guidances To Promote Competition

The US FDA has published a raft of guidances on ANDA submissions and labeling updates as well as information requests and discipline review letters.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel